Author:
Jimeno Antonio,Sharma Manish R.,Szyldergemajn Sergio,Gore Lia,Geary David,Diamond Jennifer R.,Fernandez Teruel Carlos,Soto Matos-Pita Arturo,Iglesias Jorge Luis,Cullell-Young Martin,Ratain Mark J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference8 articles.
1. Leal JF, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garcia-Fernandez LF, Galmarini CM (2010) PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 161:1099–1110
2. Santamaria Nunez G, Robles CM, Giraudon C, Martinez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM (2016) Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 15:1–14. doi: 10.1158/1535-7163.MCT-16-0172
3. Santamaria G, Avila S, Moneo V, Cuevas C, García-Fernández FC, Galmarini CM (2015) Synergistic combination of lurbinectedin and PARP inhibitors in breast cancer tumor cell lines 106th Annual Meeting of the American Association for Cancer Research:Abstract 2520
4. Allavena P, Belgiovine C, Liguori M, Bello E, Frapolli R, Galmarini CM, D'Incalci M (2016) Lurbinectedin reduces tumor-associated macrophages and the production of inflammatory cytokines, chemokines, and angiogenic factors in preclinical models. 107th Annual Meeting of the American Association for Cancer Research:Abstract 1284
5. Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ (2014) First-in-human phase I study of lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res 20:2205–2214. doi: 10.1158/1078-0432.CCR-13-1880
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献